Market Closed -
Nasdaq
04:00:00 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
2.39
USD
|
+3.91%
|
|
-4.78%
|
+298.33%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
26.01
|
19.83
|
81.03
|
21.03
|
17.29
|
85.53
|
-
|
Enterprise Value (EV)
1 |
26.01
|
19.83
|
81.03
|
21.03
|
17.29
|
85.53
|
85.53
|
P/E ratio
|
-2.4
x
|
-2
x
|
-5.99
x
|
-1.62
x
|
-1.94
x
|
-9.56
x
|
-4.43
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
54.3
x
|
142
x
|
157
x
|
-
|
-
|
-
|
EV / Revenue
|
-
|
54.3
x
|
142
x
|
157
x
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-8,923,801
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
12,154
|
18,362
|
28,784
|
28,810
|
28,814
|
35,785
|
-
|
Reference price
2 |
2.140
|
1.080
|
2.815
|
0.7300
|
0.6000
|
2.390
|
2.390
|
Announcement Date
|
3/26/20
|
3/18/21
|
3/8/22
|
3/31/23
|
3/8/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
0.365
|
0.571
|
0.134
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.45
|
-11.13
|
-12.22
|
-13.02
|
-8.891
|
-10.11
|
-28
|
Operating Margin
|
-
|
-3,050.14%
|
-2,139.58%
|
-9,714.18%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-10.8
|
-9.963
|
-12.25
|
-12.93
|
-8.86
|
-10.07
|
-28
|
Net income
1 |
-10.8
|
-9.983
|
-12.19
|
-13.07
|
-8.889
|
-10.07
|
-28
|
Net margin
|
-
|
-2,735.07%
|
-2,134.33%
|
-9,754.48%
|
-
|
-
|
-
|
EPS
2 |
-0.8900
|
-0.5400
|
-0.4700
|
-0.4500
|
-0.3100
|
-0.2500
|
-0.5400
|
Free Cash Flow
|
-
|
-
|
-9.08
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-1,590.19%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/18/21
|
3/8/22
|
3/31/23
|
3/8/24
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.165
|
0.068
|
0.044
|
0.008
|
0.014
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.115
|
-3.835
|
-3.249
|
-2.865
|
-3.068
|
-2.212
|
-2.33
|
-2.386
|
-1.932
|
-2.062
|
-2.27
|
-2.53
|
-3.25
|
-
|
-
|
Operating Margin
|
-2,493.94%
|
-5,639.71%
|
-7,384.09%
|
-35,812.5%
|
-21,914.29%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
4.734
|
-3.791
|
-3.189
|
-2.873
|
-3.081
|
-2.19
|
-2.325
|
-2.35
|
-1.995
|
-2.017
|
-2.27
|
-2.53
|
-3.25
|
-
|
-
|
Net income
1 |
4.916
|
-3.784
|
-3.185
|
-3.067
|
-3.035
|
-2.19
|
-2.325
|
-2.379
|
-1.995
|
-2.017
|
-2.27
|
-2.53
|
-3.25
|
-
|
-
|
Net margin
|
2,979.39%
|
-5,564.71%
|
-7,238.64%
|
-38,337.5%
|
-21,678.57%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
0.2100
|
-0.1300
|
-0.1100
|
-0.1100
|
-0.1000
|
-0.0800
|
-0.0800
|
-0.0800
|
-0.0700
|
-0.0500
|
-0.0600
|
-0.0600
|
-0.0700
|
-0.0800
|
-0.1100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/8/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/31/23
|
5/5/23
|
8/11/23
|
11/14/23
|
3/8/24
|
5/10/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-9.08
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.02
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
2.98%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/26/20
|
3/18/21
|
3/8/22
|
3/31/23
|
3/8/24
|
-
|
-
|
Last Close Price
2.39
USD Average target price
10
USD Spread / Average Target +318.41% Consensus |
1st Jan change
|
Capi.
|
---|
| +298.33% | 82.31M | | +8.63% | 115B | | +13.17% | 107B | | -12.76% | 22.31B | | -3.99% | 21.6B | | -7.19% | 18.23B | | -39.93% | 17.62B | | +6.67% | 14.26B | | +33.90% | 12.37B | | -28.60% | 8.28B |
Bio Therapeutic Drugs
|